JP6359517B2 - ω−３脂肪酸エステル組成物 - Google Patents

ω−３脂肪酸エステル組成物 Download PDF

Info

Publication number
JP6359517B2
JP6359517B2 JP2015503245A JP2015503245A JP6359517B2 JP 6359517 B2 JP6359517 B2 JP 6359517B2 JP 2015503245 A JP2015503245 A JP 2015503245A JP 2015503245 A JP2015503245 A JP 2015503245A JP 6359517 B2 JP6359517 B2 JP 6359517B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
ester
fatty acid
composition
acid ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015503245A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015514083A (ja
JP2015514083A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html
Inventor
サンシリオ，フレデリック
ペルシカナール，ピーター
カカーチェ，ジャニス
ダーイム，モハンド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sancilio & Company inc
Original Assignee
Sancilio & Company inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47998519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6359517(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sancilio & Company inc filed Critical Sancilio & Company inc
Publication of JP2015514083A publication Critical patent/JP2015514083A/ja
Publication of JP2015514083A5 publication Critical patent/JP2015514083A5/ja
Application granted granted Critical
Publication of JP6359517B2 publication Critical patent/JP6359517B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
JP2015503245A 2012-03-30 2013-03-11 ω−３脂肪酸エステル組成物 Expired - Fee Related JP6359517B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261618161P 2012-03-30 2012-03-30
US61/618,161 2012-03-30
PCT/US2013/030211 WO2013148136A1 (en) 2012-03-30 2013-03-11 Omega-3 fatty acid ester compositions

Publications (3)

Publication Number Publication Date
JP2015514083A JP2015514083A (ja) 2015-05-18
JP2015514083A5 JP2015514083A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2016-05-12
JP6359517B2 true JP6359517B2 (ja) 2018-07-18

Family

ID=47998519

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015503245A Expired - Fee Related JP6359517B2 (ja) 2012-03-30 2013-03-11 ω−３脂肪酸エステル組成物

Country Status (19)

Country Link
US (9) US9302017B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP2830602B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP6359517B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR102193214B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN109966279A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013240427B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2867168A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO7121328A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK3072510T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2741560T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1204978A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20191392T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (3) IL249821B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014DN08449A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX359711B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY189576A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT3072510T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2633862C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013148136A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578177A1 (en) 2008-09-02 2019-12-11 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
CA2759284C (en) 2009-04-29 2016-06-21 Amarin Pharma, Inc. Stable pharmaceutical composition and methods of using same
EP4008327A1 (en) 2009-04-29 2022-06-08 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CN108096209A (zh) 2009-06-15 2018-06-01 阿马里纳制药公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
MX2012003555A (es) 2009-09-23 2012-07-03 Amarin Corp Plc Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
EP2646013A4 (en) 2010-11-29 2014-03-26 Amarin Pharma Inc Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013103958A1 (en) 2012-01-06 2013-07-11 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
PE20142459A1 (es) 2012-01-06 2015-01-23 Omthera Pharmaceuticals Inc Composiciones enriquecidas con dpa de acidos grasos omega 3 poliinsaturados en forma de acido libre
JP6359517B2 (ja) 2012-03-30 2018-07-18 サンシリオ アンド カンパニー, インコーポレイテッドSancilio & Company, Inc. ω−３脂肪酸エステル組成物
HUE069516T2 (hu) 2012-06-29 2025-03-28 Amarin Pharmaceuticals Ie Ltd Módszerek kardiovaszkuláris esemény, kockázatainak csökkentésére sztatint szedõ alanyoknál
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
WO2015011724A2 (en) 2013-07-22 2015-01-29 Kms Health Center Pvt Ltd A novel omega -3 fatty acid composition with a plant extract
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
WO2015066512A1 (en) * 2013-10-31 2015-05-07 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
WO2016046680A2 (en) * 2014-09-27 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of liver metabolic diseases
MA40846A (fr) * 2014-10-10 2017-09-05 Sancilio & Company Inc Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'états pathologiques
MX384954B (es) * 2015-01-21 2025-03-14 Mochida Pharm Co Ltd Composición auto-emulsionante de ácido graso ?3.
MA41611A (fr) * 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
DE102015106095A1 (de) * 2015-04-21 2016-10-27 K. D. Pharma Bexbach Gmbh Neue Anwendung von Omega-3-Fettsäure(n)
WO2017033119A1 (en) * 2015-08-25 2017-03-02 Rao M Surya Compositions and methods for the treatment of liver metabolic diseases
CN116492339A (zh) * 2015-11-13 2023-07-28 深圳君圣泰生物技术有限公司 一种组合物及其用途、药物制剂
AR107143A1 (es) * 2015-12-18 2018-03-28 Afimmune Ltd Composiciones que comprenden 15-hepe y sus métodos de uso
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
AU2017232554B2 (en) * 2016-03-16 2020-05-14 Golden Omega Norway As Powders and tablets comprising omega-3 fatty acid derivatives and methods for their production
EP3496709A4 (en) * 2016-08-12 2020-04-08 Pharmako Biotechnologies PTY Limited OMEGA-3 COMPOSITIONS AND PROCEDURES
US11351127B2 (en) 2016-09-21 2022-06-07 Avexxin As Pharmaceutical composition
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
CN108354919A (zh) * 2017-12-29 2018-08-03 广东海洋大学 一种用于提高抗氧化功能的不饱和脂肪酸组合物及其应用
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
SMT202400320T1 (it) 2018-09-24 2024-09-16 Amarin Pharmaceuticals Ie Ltd Metodi di riduzione del rischio di eventi cardiovascolari in un soggetto
AU2020216162B2 (en) * 2019-02-01 2025-05-22 Mars, Incorporated Feline food composition
CN116350616A (zh) 2019-11-12 2023-06-30 阿马里纳药物爱尔兰有限公司 降低心房纤颤和/或心房扑动受试者心血管事件风险的方法
WO2021183749A1 (en) 2020-03-12 2021-09-16 Sancilio Fred D A composition comprising docosahexaenoic acid and egg yolk suitable for sickle cell disease treatment
US20230398088A1 (en) * 2020-10-30 2023-12-14 The Trustees Of The University Of Pennsylvania Lipid Prophylactic Brain Injury Treatment
WO2022225896A1 (en) 2021-04-21 2022-10-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513008A (en) 1982-07-30 1985-04-23 The Vinoxen Company, Inc. Virucidal compositions and therapy
US4992476A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Skin cleansing and moisturizing composition and method of using and preparing same
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
IE64761B1 (en) 1989-02-16 1995-09-06 British Tech Group Dispensing device
US5320798A (en) 1993-02-17 1994-06-14 Exxon Chemical Patents, Inc. Method for processing polyolefins at high shear rates
US5585192A (en) 1995-10-02 1996-12-17 Eastman Chemical Company Waterborne polyolefin adhesion promoter
DE69842121D1 (de) 1997-12-10 2011-03-17 Cyclosporine Therapeutics Ltd Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen
US6121210A (en) 1998-03-12 2000-09-19 Dap Products Inc. Foamable silicone oil compositions and methods of use thereof
IT1308613B1 (it) * 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
JP2003509453A (ja) 1999-09-21 2003-03-11 アールティーピー・ファーマ・インコーポレーテッド 生物学的に活性な物質の、表面改質された粒状組成物
NO313076B1 (no) 1999-12-28 2002-08-12 Pronova Biocare As Flytende n¶rings- og/eller nytelsesmiddel og fremgangsmåte for fremstilling derav
KR100441167B1 (ko) 2001-12-27 2004-07-21 씨제이 주식회사 마이크로에멀젼 예비 농축액 조성물
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
EP2368445A1 (en) 2002-06-18 2011-09-28 Martek Biosciences Corporation Stable Emulsions of Oils in Aqueous Solutions and Methods for Producing Same
CA2502986C (en) 2002-10-25 2011-08-23 Foamix Ltd. Cosmetic and pharmaceutical foam
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
EP1663148A2 (en) 2003-08-25 2006-06-07 Foamix Ltd. Penetrating pharmaceutical foam
AU2004289353B2 (en) 2003-11-12 2011-02-10 Children's Medical Center Corporation Treatment and prevention of liver disease associated with parenteral nutrition (PN)
SE0303513D0 (sv) 2003-12-19 2003-12-19 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
US7919526B2 (en) 2004-03-04 2011-04-05 Htl High-Tech Lipids Ltd. Structured triglycerides and emulsions comprising same
RU2007103835A (ru) 2004-07-01 2008-08-10 Шепенс Ай Рисерч (Us) Композиции и способы лечения заболеваний и нарушений состояния глаз
CN1870906A (zh) 2004-07-22 2006-11-29 德国阿奎诺瓦增溶技术有限公司 醚油和其他物质的溶解物
ITRM20040395A1 (it) * 2004-08-03 2004-11-03 Sigma Tau Ind Farmaceuti Composizione comprendente statine e acidi grassi omega 3.
SG155189A1 (en) 2004-08-06 2009-09-30 Transform Pharmaceuticals Inc Novel fenofibrate formulations and related methods of treatment
WO2006017698A2 (en) 2004-08-06 2006-02-16 Transform Pharmaceuticals, Inc. Novel statin pharmaceutical compositions and related methods of treatment
CA2577345C (en) * 2004-08-18 2013-02-19 Hiroki Ueshima Jelly composition
CN101005834A (zh) 2004-08-27 2007-07-25 千寿制药株式会社 干眼症治疗用滴眼液
US8324276B2 (en) 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
CA2600429A1 (en) 2005-03-08 2006-09-14 Reliant Pharmaceuticals, Inc. Treatment with statin and omega-3 fatty acids and a combination product thereof
US20060223737A1 (en) 2005-03-25 2006-10-05 L'oreal Foaming O/W emulsion and use thereof in cosmetics
US9968120B2 (en) 2006-05-17 2018-05-15 Dsm Nutritional Products Ag Homogenized formulations containing microcapsules and methods of making and using thereof
WO2007041409A1 (en) 2005-09-29 2007-04-12 Arena Pharmaceuticals, Inc. Pharmaceutical compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto
US20070104779A1 (en) 2005-11-07 2007-05-10 Rongen Roelof M Treatment with omega-3 fatty acids and products thereof
WO2007055327A1 (ja) * 2005-11-11 2007-05-18 Mochida Pharmaceutical Co., Ltd. ゼリー組成物
JP2009516724A (ja) 2005-11-22 2009-04-23 ネステク ソシエテ アノニム 水中油型エマルション及び機能性送達のためのその使用
JP2009520824A (ja) 2005-12-20 2009-05-28 セネストラ エルエルシー オメガ３脂肪酸製剤
US20080058418A1 (en) * 2006-09-06 2008-03-06 The Coca-Cola Company Stable polyunsaturated fatty acid emulsions and methods for inhibiting, suppressing, or reducing degradation of polyunsaturated fatty acids in an emulsion
CN101553136A (zh) * 2006-09-06 2009-10-07 可口可乐公司 稳定的多不饱和脂肪酸乳液及用于防止、抑制或降低多不饱和脂肪酸在乳液中降解的方法
EP2098222A4 (en) 2006-10-31 2012-12-26 Kaneka Corp GRANULAR COMPOSITION CONTAINING PHYSIOLOGICALLY ACTIVE SUBSTANCE AND METHOD FOR PRODUCING THE SAME
US20080306154A1 (en) 2006-11-03 2008-12-11 My Svensson Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
WO2009009040A2 (en) 2007-07-06 2009-01-15 Baum Seth J Fatty acid compositions and methods of use
US20090182049A1 (en) 2008-01-16 2009-07-16 Joar Arild Opheim Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
GB0813599D0 (en) * 2008-07-24 2008-09-03 Pharma Marine As Method
US20100062057A1 (en) 2008-09-10 2010-03-11 Pronova BioPharma Norge AS. Formulation
CN101380358B (zh) 2008-10-14 2012-12-19 沈阳药科大学 精制紫苏籽油脂肪乳注射液及制备工艺
CN104146955A (zh) * 2009-03-09 2014-11-19 普罗诺瓦生物医药挪威公司 含有脂肪酸油混合物和表面活性剂的组合物及其方法和用途
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
WO2010118761A1 (en) 2009-04-17 2010-10-21 Eolas Science Limited Compositions rich in omega-3 fatty acids with a low content in phytanic acid
EP4008327A1 (en) 2009-04-29 2022-06-08 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CA2972063C (en) 2009-05-22 2019-12-17 Mochida Pharmaceutical Co., Ltd. Self-emulsifying composition of .omega.3 fatty acid
US9480645B2 (en) 2009-06-02 2016-11-01 Abbott Medical Optics Inc. Omega-3 oil containing ophthalmic emulsions
US20110045050A1 (en) 2009-08-24 2011-02-24 Atrium Medical Corporation Nanoemulsion formulations for direct delivery
US9717703B2 (en) 2009-10-16 2017-08-01 Glaxosmithkline Llc Emulsion and emulsion preconcentrate compositions comprising omega-3 fatty acids and uses thereof are disclosed
KR102073938B1 (ko) * 2009-10-23 2020-02-05 바스프 에이에스 지방산 오일 혼합물의 코팅된 캡슐 및 정제
CN102695413A (zh) 2009-11-10 2012-09-26 麦赛尔控股有限公司 稳定的脂肪酸的制剂
JP2013537186A (ja) * 2010-09-08 2013-09-30 プロノヴァ・バイオファーマ・ノルゲ・アーエス 脂肪酸油混合物と遊離脂肪酸とスタチンとを含む組成物
US20140004186A1 (en) 2010-09-08 2014-01-02 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form, a surfactant, and a statin
AR082930A1 (es) * 2010-09-08 2013-01-16 Pronova Biopharma Norge As Composiciones que comprenden una mezcla oleosa de acidos grasos, un tensioactivo y una estatina
WO2012037328A2 (en) 2010-09-17 2012-03-22 Maine Natural Health, Inc. Compositions containing omega-3 oil with an anti-inflammatory agent and uses thereof
US20130203701A1 (en) 2010-09-17 2013-08-08 Maine Natural Health, Inc. Compositions containing omega-3 oil and uses thereof
HK1207966A1 (en) 2012-02-16 2016-02-19 布莱特赛德创新有限公司 Dietary and nutritional compositions and methods of use
JP6359517B2 (ja) 2012-03-30 2018-07-18 サンシリオ アンド カンパニー, インコーポレイテッドSancilio & Company, Inc. ω−３脂肪酸エステル組成物

Also Published As

Publication number Publication date
JP2015514083A (ja) 2015-05-18
EP2830602B1 (en) 2020-10-21
AU2013240427A1 (en) 2014-09-25
US20150328325A1 (en) 2015-11-19
US9364562B2 (en) 2016-06-14
RU2014141406A (ru) 2016-05-20
US9370585B2 (en) 2016-06-21
US20150328177A1 (en) 2015-11-19
US20150328178A1 (en) 2015-11-19
IL234814A (en) 2017-11-30
EP3072510B1 (en) 2019-05-08
EP3072510A1 (en) 2016-09-28
US20150328324A1 (en) 2015-11-19
US9302017B2 (en) 2016-04-05
US20150328327A1 (en) 2015-11-19
US20140348929A1 (en) 2014-11-27
MX2014011596A (es) 2015-07-06
US9364558B2 (en) 2016-06-14
IN2014DN08449A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-05-08
US9375490B2 (en) 2016-06-28
CN109966279A (zh) 2019-07-05
KR20140145597A (ko) 2014-12-23
IL249821B (en) 2019-04-30
US9302016B2 (en) 2016-04-05
US20150328153A1 (en) 2015-11-19
DK3072510T3 (da) 2019-08-12
US9364560B2 (en) 2016-06-14
HRP20191392T1 (hr) 2019-12-27
WO2013148136A1 (en) 2013-10-03
CN104321053A (zh) 2015-01-28
MY189576A (en) 2022-02-17
US9364559B2 (en) 2016-06-14
RU2633862C2 (ru) 2017-10-18
EP2830602A1 (en) 2015-02-04
KR102193214B1 (ko) 2020-12-18
AU2013240427B2 (en) 2017-08-03
CA2867168A1 (en) 2013-10-03
US20150328326A1 (en) 2015-11-19
IL249821A0 (en) 2017-02-28
US9364561B2 (en) 2016-06-14
CO7121328A2 (es) 2014-11-20
PT3072510T (pt) 2019-08-22
ES2741560T3 (es) 2020-02-11
HK1204978A1 (en) 2015-12-11
US20140348930A1 (en) 2014-11-27
MX359711B (es) 2018-10-08

Similar Documents

Publication Publication Date Title
JP6359517B2 (ja) ω−３脂肪酸エステル組成物
WO2007055327A1 (ja) ゼリー組成物
US20210324302A1 (en) Omega-3 fatty acid ester compositions
US20160228398A1 (en) Omega-3 fatty acid ester compositions
US20150132389A1 (en) Omega-3 Fatty Acid Ester Compositions
US20150125529A1 (en) Omega-3 Fatty Acid Ester Compositions
US9480651B2 (en) Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
US20160235853A1 (en) Omega-3 fatty acid ester compositions
US20150125530A1 (en) Omega-3 Fatty Acid Ester Compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170407

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180301

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180425

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180522

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180620

R150 Certificate of patent or registration of utility model

Ref document number: 6359517

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees